Champions Oncology, Inc. (CSBR) Earnings History
Annual and quarterly earnings data from 1996 to 2025
Loading earnings history...
CSBR EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CSBR Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 47.3% | 8.5% | 8.3% |
| 2024 | 41.4% | -13.8% | -14.5% |
| 2023 | 45.2% | -8.3% | -9.9% |
| 2022 | 51.9% | 1.2% | 1.1% |
| 2021 | 47.7% | 0.9% | 0.9% |
Download Data
Export CSBR earnings history in CSV or JSON format
Free sign-in required to download data
Champions Oncology, Inc. (CSBR) Earnings Overview
As of May 8, 2026, Champions Oncology, Inc. (CSBR) reported trailing twelve-month net income of -$2M, reflecting +161.1% year-over-year growth. The company earned $-0.16 per diluted share over the past four quarters, with a net profit margin of 8.3%.
Looking at the long-term picture, CSBR's historical earnings data spans multiple years. The company achieved its highest annual net income of $5M in fiscal 2025, representing a new all-time high.
Champions Oncology, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), CASI (-$49M net income, -137.6% margin), TPVG (-$12M net income, 50.6% margin), CSBR has comparable earnings metrics. Compare CSBR vs IMVT →
CSBR Earnings vs Peers
Earnings metrics vs comparable public companies
CSBR Historical Earnings Data (1996–2025)
30 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $5M | +164.6% | $5M | $0.33 | 8.3% | 8.5% |
| 2024 | -$7M | -36.4% | -$7M | $-0.54 | -14.5% | -13.8% |
| 2023 | -$5M | -1073.5% | -$4M | $-0.39 | -9.9% | -8.3% |
| 2022 | $548,000 | +51.4% | $607,000 | $0.04 | 1.1% | 1.2% |
| 2021 | $362,000 | +117.3% | $366,000 | $0.02 | 0.9% | 0.9% |
| 2020 | -$2M | -1735.2% | -$2M | $-0.18 | -6.5% | -4.9% |
| 2019 | $128,000 | +108.7% | $270,000 | $0.01 | 0.5% | 1.0% |
| 2018 | -$1M | +78.6% | -$1M | $-0.13 | -7.3% | -6.7% |
| 2017 | -$7M | +34.1% | -$7M | $-0.63 | -44.7% | -44.2% |
| 2016 | -$10M | +20.5% | -$10M | $-1.20 | -93.4% | -92.3% |
See CSBR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CSBR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CSBR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCSBR — Frequently Asked Questions
Quick answers to the most common questions about buying CSBR stock.
Is CSBR growing earnings?
CSBR EPS is $-0.16, with earnings growth accelerating to +161.1%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-2M.
What are CSBR's profit margins?
Champions Oncology, Inc. net margin is +8.3%, with operating margin at +8.5%. Margins sit within typical range for the sector.
How consistent are CSBR's earnings?
CSBR earnings data spans 1996-2025. The accelerating earnings trend is +161.1% YoY. Historical data enables comparison across business cycles.